Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co ElifiledCriticalLilly Co Eli
Priority claimed from PCT/US2014/039494external-prioritypatent/WO2014193781A1/en
Publication of MA38636A1publicationCriticalpatent/MA38636A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
L'invention concerne certains composés de 3,4-dihydroisoquinoléin-2(1h)-yle, notamment des composés de formule (i), et des compositions pharmaceutiques correspondantes. L'invention concerne en outre des procédés d'utilisation d'un composé de formule (i) pour traiter la déficience cognitive associée à la maladie de parkinson ou à la schizophrénie.The invention relates to certain 3,4-dihydroisoquinolin-2 (1h) -yl compounds, especially compounds of formula (i), and corresponding pharmaceutical compositions. The invention further provides methods of using a compound of formula (i) to treat cognitive impairment associated with Parkinson's disease or schizophrenia.
N- [4- (quinolin-4-yloxy) cyclohexyl (methyl)] (hetero) arylcarboxamides for use as androgen receptor antagonists, their production and their use as medicaments